Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1602195

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1602195

Travel Vaccines Market by Type (Attenuated Vaccines, Conjugate Vaccines, DNA Vaccines), Disease (DPT, Hepatitis A, Hepatitis B) - Global Forecast 2025-2030

PUBLISHED:
PAGES: 193 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Travel Vaccines Market was valued at USD 8.26 billion in 2023, expected to reach USD 9.09 billion in 2024, and is projected to grow at a CAGR of 10.06%, to USD 16.18 billion by 2030.

Travel vaccines, also known as travel immunizations, are crucial for ensuring the health safety of individuals traveling to regions with prevalent infectious diseases. The necessity of travel vaccines stems from their role in preventing travelers from contracting diseases such as yellow fever, hepatitis A, and typhoid, which are prevalent in certain geographical areas. Their application is primarily focused on individuals who travel internationally, and they find end-use across segments such as individual tourists, business travelers, military personnel, and expatriates.

KEY MARKET STATISTICS
Base Year [2023] USD 8.26 billion
Estimated Year [2024] USD 9.09 billion
Forecast Year [2030] USD 16.18 billion
CAGR (%) 10.06%

A significant factor influencing the growth of this market is the increasing international travel frequency, driven by globalization, tourism, and business expansion. Additionally, heightened awareness of health risks and stringent regulations by health authorities also propel the market forward. Technological advancements in vaccine development, such as the introduction of combination vaccines, present further opportunities. For businesses to capitalize, investing in the development of vaccines with longer-lasting protection and fewer side effects is recommended. Moreover, digital platforms for disseminating travel vaccine information can expand market reach.

However, the market is faced with challenges, such as the high cost of developing new vaccines and regulatory hurdles that can delay market entry. Public resistance to vaccination and misinformation can also hinder market growth. Furthermore, supply chain disruptions, as observed during global health crises, can impede availability.

Areas ripe for innovation include the research and development of vaccines against emerging diseases, personalized vaccine schedules based on traveler profiles, and enhanced vaccine delivery mechanisms, such as micro-needle patches. The market is dynamic, influenced by geopolitical and environmental changes, which necessitate vigilance and adaptability from market players to address emerging health threats. To effectively navigate these challenges and seize opportunities, market players must focus on collaboration with health organizations, leverage data analytics for market forecasting, and maintain robust communication strategies to counter misinformation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Travel Vaccines Market

The Travel Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Popularity of International Tourism
    • Growing Prevalence of Infectious Diseases and Development of Combination Vaccines
    • Recent Investments and Improvement in Cold Chain Storage Infrastructure
  • Market Restraints
    • Limited Awareness Amongst Travelers
  • Market Opportunities
    • Innovations in Novel Vaccine Technologies and Advancements
    • Government and Organizational Funding and Initiatives for Immunization and Vaccine Development
  • Market Challenges
    • Issues Related to Vaccine Handling and Storage

Porter's Five Forces: A Strategic Tool for Navigating the Travel Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Travel Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Travel Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Travel Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Travel Vaccines Market

A detailed market share analysis in the Travel Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Travel Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Travel Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Travel Vaccines Market, highlighting leading vendors and their innovative profiles. These include Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Cadila Pharmaceuticals Limited, Shenzhen Kangtai Biological Products Co., Ltd., Novartis AG, Dynavax Technologies Corporation, CSL Limited, Emergent BioSolutions Inc., Bio-Med (P) Limited, Bharat Biotech Ltd., Indian Immunologicals Ltd., Dano Vaccines & Biologicals Private Limited, Bavarian Nordic A/S, Johnson & Johnson Services, Inc, Pfizer Inc., Incepta Pharmaceuticals Ltd., GlaxoSmithKline PLC, Serum Institute of India Pvt. Ltd., Abbott Laboratories, AstraZeneca PLC, Walvax Biotechnology Co., Ltd., Bio-Manguinhos, Valneva SE, Sanofi S.A., and Biological E Limited.

Market Segmentation & Coverage

This research report categorizes the Travel Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Attenuated Vaccines, Conjugate Vaccines, DNA Vaccines, Inactive Vaccines, Recombinant Vector Vaccines, Subunit Vaccines, and Toxoid Vaccines.
  • Based on Disease, market is studied across DPT, Hepatitis A, Hepatitis B, Japanese Encephalitis, Measles and Mumps, Meningococcal, Rabies, Typhoid, Varicella, and Yellow Fever.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-0316851957A3

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Popularity of International Tourism
      • 5.1.1.2. Growing Prevalence of Infectious Diseases and Development of Combination Vaccines
      • 5.1.1.3. Recent Investments and Improvement in Cold Chain Storage Infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. Limited Awareness Amongst Travelers
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in Novel Vaccine Technologies and Advancements
      • 5.1.3.2. Government and Organizational Funding and Initiatives for Immunization and Vaccine Development
    • 5.1.4. Challenges
      • 5.1.4.1. Issues Related to Vaccine Handling and Storage
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Advancements in DNA vaccines to induce immune response
    • 5.2.2. Disease: Need based preference for hepatitis vaccines among travelers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Travel Vaccines Market, by Type

  • 6.1. Introduction
  • 6.2. Attenuated Vaccines
  • 6.3. Conjugate Vaccines
  • 6.4. DNA Vaccines
  • 6.5. Inactive Vaccines
  • 6.6. Recombinant Vector Vaccines
  • 6.7. Subunit Vaccines
  • 6.8. Toxoid Vaccines

7. Travel Vaccines Market, by Disease

  • 7.1. Introduction
  • 7.2. DPT
  • 7.3. Hepatitis A
  • 7.4. Hepatitis B
  • 7.5. Japanese Encephalitis
  • 7.6. Measles and Mumps
  • 7.7. Meningococcal
  • 7.8. Rabies
  • 7.9. Typhoid
  • 7.10. Varicella
  • 7.11. Yellow Fever

8. Americas Travel Vaccines Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Travel Vaccines Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Travel Vaccines Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. India's First Indigenously Developed Hepatitis A Vaccine Launched In Hyderabad
    • 11.3.2. FDA Approves PENBRAYA, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
    • 11.3.3. Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

Companies Mentioned

  • 1. Merck & Co., Inc.
  • 2. Takeda Pharmaceutical Company Limited
  • 3. Cadila Pharmaceuticals Limited
  • 4. Shenzhen Kangtai Biological Products Co., Ltd.
  • 5. Novartis AG
  • 6. Dynavax Technologies Corporation
  • 7. CSL Limited
  • 8. Emergent BioSolutions Inc.
  • 9. Bio-Med (P) Limited
  • 10. Bharat Biotech Ltd.
  • 11. Indian Immunologicals Ltd.
  • 12. Dano Vaccines & Biologicals Private Limited
  • 13. Bavarian Nordic A/S
  • 14. Johnson & Johnson Services, Inc
  • 15. Pfizer Inc.
  • 16. Incepta Pharmaceuticals Ltd.
  • 17. GlaxoSmithKline PLC
  • 18. Serum Institute of India Pvt. Ltd.
  • 19. Abbott Laboratories
  • 20. AstraZeneca PLC
  • 21. Walvax Biotechnology Co., Ltd.
  • 22. Bio-Manguinhos
  • 23. Valneva SE
  • 24. Sanofi S.A.
  • 25. Biological E Limited
Product Code: MRR-0316851957A3

LIST OF FIGURES

  • FIGURE 1. TRAVEL VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. TRAVEL VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TRAVEL VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TRAVEL VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INACTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RECOMBINANT VECTOR VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TRAVEL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DPT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TRAVEL VACCINES MARKET SIZE, BY JAPANESE ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MEASLES AND MUMPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 51. JAPAN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 53. MALAYSIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. MALAYSIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 55. PHILIPPINES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. PHILIPPINES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 57. SINGAPORE TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. SINGAPORE TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 61. TAIWAN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. TAIWAN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 63. THAILAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. THAILAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 65. VIETNAM TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. VIETNAM TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. DENMARK TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. DENMARK TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 72. EGYPT TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. EGYPT TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. FINLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. FINLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 76. FRANCE TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. FRANCE TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. GERMANY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. GERMANY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 80. ISRAEL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. ISRAEL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 82. ITALY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. ITALY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. NETHERLANDS TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. NETHERLANDS TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 86. NIGERIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. NIGERIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 88. NORWAY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. NORWAY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. POLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. POLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 92. QATAR TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. QATAR TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. RUSSIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. RUSSIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. SAUDI ARABIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SAUDI ARABIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH AFRICA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH AFRICA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 100. SPAIN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SPAIN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. SWEDEN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SWEDEN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. SWITZERLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SWITZERLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 106. TURKEY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. TURKEY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED ARAB EMIRATES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED ARAB EMIRATES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 112. TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 113. TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!